Gera Ritika, Tayeh Salim, Chehade Hiba El-Hage, Mokbel Kefah
London Breast Institute, London, U.K.
Anticancer Res. 2018 Dec;38(12):6615-6620. doi: 10.21873/anticanres.13028.
BACKGROUND/AIM: Hypoactive sexual desire disorder (HSDD) is hypothesised to manifest in postmenopausal women at onset of menopause due to decreased oestrogen levels. Transdermal testosterone is a potential treatment option. This systematic review explores the relationship between the incidence of breast cancer and transdermal testosterone use.
Searches were conducted on the PubMed and Ovid databases. In Ovid, the advanced search function was used: 'transdermal testosterone not male'. In PubMed, the following search terms were used: 'transdermal, testosterone, menopausal, women, breast cancer, women'. Abstracts that fitted our initial criteria were further investigated.
A total of 25 publications from PubMed and 192 publications from Ovid were initially assessed. Three randomised control trials were judged to have sufficiently met our inclusion criteria. However, these trials were too heterogeneous for a meta-analysis. A systematic review was deemed the most appropriate analysis of the data available.
The publications examined in this systematic review suggest that the use of transdermal testosterone to treat HSDD in postmenopausal women does not increase breast cancer incidence. However, further research in the form of adequately powered randomised controlled trials with breast cancer incidence being the primary end point is required in order to confirm this.
背景/目的：低活性性欲障碍（HSDD）被认为在绝经后女性绝经开始时由于雌激素水平降低而出现。经皮睾酮是一种潜在的治疗选择。本系统评价探讨乳腺癌发病率与经皮睾酮使用之间的关系。
在PubMed和Ovid数据库进行检索。在Ovid中，使用高级检索功能：“经皮睾酮非男性”。在PubMed中，使用以下检索词：“经皮、睾酮、绝经、女性、乳腺癌、妇女”。对符合我们初始标准的摘要进行进一步研究。
最初评估了来自PubMed的25篇出版物和来自Ovid的192篇出版物。三项随机对照试验被判定充分符合我们的纳入标准。然而，这些试验对于荟萃分析来说异质性太大。系统评价被认为是对现有数据最合适的分析方法。
本系统评价中审查的出版物表明，在绝经后女性中使用经皮睾酮治疗HSDD不会增加乳腺癌发病率。然而，需要以乳腺癌发病率为主要终点的充分有力的随机对照试验形式进行进一步研究以证实这一点。
